Dolby Laboratories Inc. (DLB)
Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain
Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA's feedback gave their planned pivotal program a clearer path. Basically, DLB psychosis has no approved therapy, and zervimesine is a promising oral once-daily drug that already has interesting Phase 2 data. CGTX's SHIMMER trial was a good start, but their next trial must confirm longer-lasting hallucination and delusion benefits.
3 Audio Video Stocks to Watch as Industry Witnesses Headwinds
Amid cautious discretionary spending and macro troubles, investments in cutting-edge solutions are likely to aid Zacks Audio Video Production industry participants like SONY, DLB and SONO.
Dolby Laboratories, Inc. (DLB) Presents at 2026 Baird Global Consumer, Technology & Services Conference Transcript
Dolby Laboratories, Inc. (DLB) Presents at 2026 Baird Global Consumer, Technology & Services Conference Transcript
Dolby Laboratories, Inc. (DLB) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Dolby Laboratories, Inc. (DLB) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Dolby: I Don't Mind Waiting In 2026
Dolby Labs is rated a 'BUY' with a conservative $80/share price target, reflecting 17–25% annualized upside potential through 2028. DLB trades at a rare sub-15x P/E, supported by robust patent-driven recurring revenue, high margins, and a net cash balance exceeding $500M. Despite cyclical end-market exposure and recent earnings volatility, DLB's technology leadership and dominant licensing position underpin long-term revenue security.
Dolby Q2 Earnings Top Estimates on Licensing Strength, Revenues Up Y/Y
DLB beats Q2 estimates as licensing growth, strong broadcast demand and expanding Dolby Atmos adoption drive revenue and a steady outlook.
Dolby Laboratories, Inc. (DLB) Q2 2026 Earnings Call Transcript
Dolby Laboratories, Inc. (DLB) Q2 2026 Earnings Call Transcript
Compared to Estimates, Dolby Laboratories (DLB) Q2 Earnings: A Look at Key Metrics
The headline numbers for Dolby Laboratories (DLB) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Dolby Laboratories (DLB) Q2 Earnings and Revenues Top Estimates
Dolby Laboratories (DLB) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $1.31 per share. This compares to earnings of $1.34 per share a year ago.
Dolby Labs Has Easy 30% Upside
Dolby Laboratories (DLB) offers a compelling risk-reward profile with high margins, robust free cash flow, and a reasonable valuation. DLB's intrinsic value is estimated near $80 per share, implying 36% upside from current levels and supporting a double-digit annual return outlook. Growth is driven by expanding automotive, mobile, and streaming partnerships, with 93% of sales from licensing and strong IP protection.
3 Audio Video Stocks to Buy as Industry Tailwinds Gain Momentum
Investments in cutting-edge and innovative solutions are likely to aid Zacks Audio Video Production industry participants like DLB, SONO and LVO amid cautious discretionary spending.
Dynamic Technology Lab Private Ltd Has $274,000 Stock Holdings in Dolby Laboratories $DLB
Dynamic Technology Lab Private Ltd reduced its position in shares of Dolby Laboratories (NYSE: DLB) by 79.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,791 shares of the electronics maker's stock after selling 14,739
